A phase II trial of SENS-401 to prevent cisplatin-induced ototoxicity in a pediatric population
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2018
At a glance
- Drugs R-azasetron-besylate (Primary)
- Indications Chemotherapy-induced damage
- Focus Therapeutic Use
- 24 Jan 2018 According to a Sensorion media release, phase 2 clinical program is expected to begin in the first half of 2018.
- 21 Oct 2017 New trial record
- 17 Oct 2017 This trial is expected to begin in the second half of 2018, according to a Sensorion media release.